These findings support the approved treatment of the 18 mg QD starting dose of lenvatinib in combination with everolimus as an effective treatment option for patients with RCC following one prior VEGF-targeted treatment while maintaining QOL. Here, VEGFA is linked to renal cell carcinoma.